Tags

Type your tag names separated by a space and hit enter

Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study.
Malar J. 2012 Oct 29; 11:356.MJ

Abstract

BACKGROUND

Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy.

METHODS

Four intervention districts were purposefully selected to receive branded subsidized medicines - "ACT with a leaf", while the fifth district acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at licensed and unlicensed drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention's impact on: ACT uptake and price; purchase of ACT within 24 hours of symptom onset; ACT availability and displacement of sub-optimal anti-malarial.

RESULTS

At baseline, ACT accounted for less than 1% of anti-malarials purchased from licensed drug shops for children less than five years old. However, at evaluation, "ACT with a leaf" accounted for 69% of anti-malarial purchased in the interventions districts. Purchase of ACT within 24 hours of symptom onset for children under five years rose from 0.8% at baseline to 26.2% (95% CI: 23.2-29.2%) at evaluation in the intervention districts. In the control district, it rose modestly from 1.8% to 5.6% (95% CI: 4.0-7.3%). The odds of purchasing ACT within 24 hours in the intervention districts compared to the control was 0.46 (95% CI: 0.08-2.68, p=0.4) at baseline and significant increased to 6.11 (95% CI: 4.32-8.62, p<0.0001) at evaluation. Children less than five years of age had "ACT with a leaf" purchased for them more often than those aged above five years. There was no evidence of price gouging.

CONCLUSIONS

These data demonstrate that a supply-side subsidy and an intensive communications campaign significantly increased the uptake and use of ACT in the private sector in Uganda.

Authors+Show Affiliations

Medicines for Malaria Venture-MMV, PO Box 1826 20, rte de Pré-Bois, Geneva 15, 1215, Switzerland. atalisuna@nairobi.kemri-wellcome.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23107021

Citation

Talisuna, Ambrose O., et al. "Closing the Access Barrier for Effective Anti-malarials in the Private Sector in Rural Uganda: Consortium for ACT Private Sector Subsidy (CAPSS) Pilot Study." Malaria Journal, vol. 11, 2012, p. 356.
Talisuna AO, Daumerie PG, Balyeku A, et al. Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study. Malar J. 2012;11:356.
Talisuna, A. O., Daumerie, P. G., Balyeku, A., Egan, T., Piot, B., Coghlan, R., Lugand, M., Bwire, G., Rwakimari, J. B., Ndyomugyenyi, R., Kato, F., Byangire, M., Kagwa, P., Sebisubi, F., Nahamya, D., Bonabana, A., Mpanga-Mukasa, S., Buyungo, P., Lukwago, J., ... Jagoe, G. (2012). Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study. Malaria Journal, 11, 356. https://doi.org/10.1186/1475-2875-11-356
Talisuna AO, et al. Closing the Access Barrier for Effective Anti-malarials in the Private Sector in Rural Uganda: Consortium for ACT Private Sector Subsidy (CAPSS) Pilot Study. Malar J. 2012 Oct 29;11:356. PubMed PMID: 23107021.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Closing the access barrier for effective anti-malarials in the private sector in rural Uganda: consortium for ACT private sector subsidy (CAPSS) pilot study. AU - Talisuna,Ambrose O, AU - Daumerie,Penny Grewal, AU - Balyeku,Andrew, AU - Egan,Timothy, AU - Piot,Bram, AU - Coghlan,Renia, AU - Lugand,Maud, AU - Bwire,Godfrey, AU - Rwakimari,John Bosco, AU - Ndyomugyenyi,Richard, AU - Kato,Fred, AU - Byangire,Maria, AU - Kagwa,Paul, AU - Sebisubi,Fred, AU - Nahamya,David, AU - Bonabana,Angela, AU - Mpanga-Mukasa,Susan, AU - Buyungo,Peter, AU - Lukwago,Julius, AU - Batte,Allan, AU - Nakanwagi,Grace, AU - Tibenderana,James, AU - Nayer,Kinny, AU - Reddy,Kishore, AU - Dokwal,Nilesh, AU - Rugumambaju,Sylvester, AU - Kidde,Saul, AU - Banerji,Jaya, AU - Jagoe,George, Y1 - 2012/10/29/ PY - 2012/09/18/received PY - 2012/10/25/accepted PY - 2012/10/31/entrez PY - 2012/10/31/pubmed PY - 2013/4/30/medline SP - 356 EP - 356 JF - Malaria journal JO - Malar J VL - 11 N2 - BACKGROUND: Artemisinin-based combination therapy (ACT), the treatment of choice for uncomplicated falciparum malaria, is unaffordable and generally inaccessible in the private sector, the first port of call for most malaria treatment across rural Africa. Between August 2007 and May 2010, the Uganda Ministry of Health and the Medicines for Malaria Venture conducted the Consortium for ACT Private Sector Subsidy (CAPSS) pilot study to test whether access to ACT in the private sector could be improved through the provision of a high level supply chain subsidy. METHODS: Four intervention districts were purposefully selected to receive branded subsidized medicines - "ACT with a leaf", while the fifth district acted as the control. Baseline and evaluation outlet exit surveys and retail audits were conducted at licensed and unlicensed drug outlets in the intervention and control districts. A survey-adjusted, multivariate logistic regression model was used to analyse the intervention's impact on: ACT uptake and price; purchase of ACT within 24 hours of symptom onset; ACT availability and displacement of sub-optimal anti-malarial. RESULTS: At baseline, ACT accounted for less than 1% of anti-malarials purchased from licensed drug shops for children less than five years old. However, at evaluation, "ACT with a leaf" accounted for 69% of anti-malarial purchased in the interventions districts. Purchase of ACT within 24 hours of symptom onset for children under five years rose from 0.8% at baseline to 26.2% (95% CI: 23.2-29.2%) at evaluation in the intervention districts. In the control district, it rose modestly from 1.8% to 5.6% (95% CI: 4.0-7.3%). The odds of purchasing ACT within 24 hours in the intervention districts compared to the control was 0.46 (95% CI: 0.08-2.68, p=0.4) at baseline and significant increased to 6.11 (95% CI: 4.32-8.62, p<0.0001) at evaluation. Children less than five years of age had "ACT with a leaf" purchased for them more often than those aged above five years. There was no evidence of price gouging. CONCLUSIONS: These data demonstrate that a supply-side subsidy and an intensive communications campaign significantly increased the uptake and use of ACT in the private sector in Uganda. SN - 1475-2875 UR - https://www.unboundmedicine.com/medline/citation/23107021/Closing_the_access_barrier_for_effective_anti_malarials_in_the_private_sector_in_rural_Uganda:_consortium_for_ACT_private_sector_subsidy__CAPSS__pilot_study_ L2 - https://malariajournal.biomedcentral.com/articles/10.1186/1475-2875-11-356 DB - PRIME DP - Unbound Medicine ER -